EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Reprogramming resistance: phage-antibiotic synergy targets efflux systems in ESKAPEE pathogens

Anita Tarasenko iD, Bhavya N Papudeshi iD, Susanna R Grigson iD, Vijini Mallawaarachchi, Abbey L K Hutton iD, Morgyn S Warner, Jeremy J Barr iD, Jon Iredell, Bart Eijkelkamp iD, Robert A Edwards

mBio · 08.10.2025 · 16 (10)

DOI: 10.1128/mbio.01822-25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift mBio, erschienen am 08.10.2025. Verfasst von Anita Tarasenko und 9 weiteren Autor:innen. Beteiligte Einrichtung: Flinders Accelerator for Microbiome Exploration, College of Science and Engineering, Flinders University, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Bacteriophages, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Bacterial Infections. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Australian Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) ESKAPE pathogens pose a significant global health threat due to their ability to evade antibiotics through intrinsic and acquired mechanisms. These bacteria, including Enterococcus faecium , Staphylococcus aureus , Klebsiella pneumoniae , Acinetobacter baumannii , Pseudomonas aeruginosa , Escherichia coli, and Enterobacter species, evade antibiotics through intrinsic and adaptive mechanisms. Common strategies include capsule formation, biofilm, β-lactamase production, and efflux activity. Using these mechanisms, bacteria can evade the effects of antibiotics, leading to persistent and difficult-to-treat infections. Understanding the mechanisms of resistance is crucial in developing effective strategies to combat MDR and XDR ESKAPEE pathogens. A promising approach is the development of alternative treatments targeting specific resistance mechanisms in these pathogens. Bacteriophages (phages), which co-evolve with bacterial hosts, offer a dynamic therapeutic alternative by targeting pathogenic bacteria using precision-based strategies. This targeted approach can overcome antibiotic resistance and reduce the risk of damaging the beneficial microbiota. Phages can restore susceptibility in previously untreatable infections by enhancing antibiotic uptake and imposing fitness costs on resistant strains. However, therapeutic deployment faces challenges such as rapid evolution of phage resistance, inconsistent production standards, and limited regulatory pathways. This review examines the mechanistic insights into phage-antibiotic synergy, with a focus on efflux pump-mediated resistance. It discusses emerging therapeutic strategies, current clinical applications, and the translational frameworks needed to integrate phage therapy into mainstream medicine and transform the clinical management of drug-resistant ESKAPEE infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BacteriophagesAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialBacterial InfectionsBacteriaHumansPhage Therapy

Stichwörter der Autor:innen

ESKAPEE pathogensefflux pump inhibitionmultidrug resistance (MDR)phage therapyphage-antibiotic synergy

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Flinders Accelerator for Microbiome Exploration, College of Science and Engineering, Flinders University, Adelaide, South Australia, Australia.
  • Microbiology & Infectious Diseases Directorate, SA Pathology, Central Adelaide Local Health Network, Adelaide, South Australia, Australia.
  • Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia.
  • School of Biological Sciences, Monash University, Melbourne, Victoria, Australia.
  • Centre for Infectious Diseases and Microbiology, The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
  • Faculty of Medicine and Health, University of Sydney, , Sydney, New South Wales, Australia.

ORCID-Profile: Anita Tarasenko, Bhavya N Papudeshi, Susanna R Grigson, Abbey L K Hutton, Jeremy J Barr, Bart Eijkelkamp

Förderung

  • NIDDK NIH HHS
  • Australian Research Council

Zitieren

APA

Tarasenko, A., Papudeshi, B. N., Grigson, S. R., Mallawaarachchi, V., Hutton, A. L. K., Warner, M. S., Barr, J. J., Iredell, J., Eijkelkamp, B., & Edwards, R. A. (2025). Reprogramming resistance: phage-antibiotic synergy targets efflux systems in ESKAPEE pathogens. mBio, 16(10). https://doi.org/10.1128/mbio.01822-25

Vancouver

Tarasenko A, Papudeshi BN, Grigson SR, Mallawaarachchi V, Hutton ALK, Warner MS, et al. Reprogramming resistance: phage-antibiotic synergy targets efflux systems in ESKAPEE pathogens. mBio. 2025;16(10). doi:10.1128/mbio.01822-25

BibTeX
@article{Tarasenko2025,
  author = {Tarasenko, Anita and Papudeshi, Bhavya N and Grigson, Susanna R and Mallawaarachchi, Vijini and Hutton, Abbey L K and Warner, Morgyn S and Barr, Jeremy J and Iredell, Jon and Eijkelkamp, Bart and Edwards, Robert A},
  title = {Reprogramming resistance: phage-antibiotic synergy targets efflux systems in ESKAPEE pathogens},
  journal = {mBio},
  year = {2025},
  volume = {16},
  number = {10},
  doi = {10.1128/mbio.01822-25}
}
Kostenlos starten →